Lab-grown fabric is real, functional, and in some cases already on store shelves — but whether it represents a genuine ecological shift or an elaborate marketing exercise depends almost entirely on which company you're looking at, what metrics you're using, and how honest you're willing to be about scale.
The pitch sounds clean. Grow leather in a bioreactor. Spin silk without silkworms. Engineer mycelium into a material that behaves like suede. No factory farms, no toxic tanning chemicals, no petroleum-based polyester flooding the ocean with microplastics. The fashion industry — responsible for somewhere between 4% and 10% of global greenhouse gas emissions depending on whose methodology you trust — finally gets its sustainable future, and it comes from a lab.
Except the reality is messier than that. Much messier.
What Synthetic Biology Actually Means in This Context
Synthetic biology, in the fashion context, typically refers to one of a few distinct approaches: using engineered microorganisms (yeast, bacteria, algae) to produce materials or fibers, growing animal-free leather alternatives from mycelium (fungal root networks) or cell-cultured collagen, or biosynthesizing polymers that mimic conventional materials without petrochemical feedstocks.
These are not the same thing, and conflating them is one of the biggest sources of confusion in coverage of this space.
Mycelium leather — made by companies like Bolt Threads (their product: Mylo) and Ecovative — grows fungal networks on agricultural waste substrates. The material is then processed, often including a backing layer, and finished to behave like leather. Stella McCartney used Mylo in a prototype bag. Hermès announced a collaboration with Bolt Threads for a product called Sylvania. Both of these got enormous press. Neither is in full commercial production at meaningful scale.
Biofabricated silk and spider silk — Bolt Threads also produced a synthetic spider silk called Microsilk, engineered from yeast. The protein sequence mimics spider dragline silk, which is extraordinarily strong relative to weight. The technical achievement is real. But Bolt Threads quietly shelved consumer Microsilk products after limited capsule drops. The economics didn't work.
Cell-cultured leather — companies like Modern Meadow have grown actual collagen-based materials using cell culture techniques borrowed from the biomedical world. The material science is impressive. The cost is not.
The Scale Problem Nobody Wants to Talk About
Here's where the hype and the reality start to diverge.
Bioreactors are expensive to build, operate, and maintain. Scaling fermentation-based material production runs into the same fundamental constraints as scaling cultured meat: you need enormous quantities of growth media, precise environmental controls, significant energy inputs, and facilities that cost hundreds of millions of dollars to construct. The per-square-meter cost of most bioengineered leather alternatives is, by most industry estimates, still multiples higher than conventional leather — and often higher than high-quality synthetic alternatives.
A Mylo bag from Stella McCartney, when it was available, cost around the price of a conventional luxury leather bag. That sounds fine until you realize that's a luxury brand absorbing enormous margin compression to make the economics work at all, and even then only for a small collector's item, not a scalable product line.
"Works great until you actually scale it" is not an exaggeration here. It's basically the entire structural problem of the bioeconomy for textiles.
The fermentation infrastructure required to produce, say, enough biofabricated material to replace even 1% of global leather production doesn't currently exist. Building it would require capital investment that hasn't materialized, in part because the fashion industry's economics don't naturally support long infrastructure timelines.
Who's Actually Buying This and Why
The customer base for bioengineered fashion materials currently splits into two groups that barely overlap.
The first is the luxury segment, where brands use partnerships with biotech startups as a form of reputational signaling. Hermès, Stella McCartney, Adidas (which collaborated with Bolt Threads on a Futurecraft shoe using Mylo) — these are brands for whom the cost premium is absorbable and the PR value is real. For them, announcing a mycelium collaboration communicates innovation and sustainability alignment to a customer base that cares about those signals, whether or not the product ever reaches meaningful production.
The second is a smaller group of genuinely committed sustainability buyers who will pay a premium specifically because of the material's origins. These customers exist, but the market is thin.
What's notably absent: the mass market. H&M, Zara, Amazon Fashion. The segment that actually drives volume. For them, bioengineered materials are currently nowhere near price-competitive.
The Greenwashing Accusation Isn't Entirely Fair — But It's Not Wrong Either
There's a spectrum here.